Robert Barrie

Regeneron has won US Food and Drug Administration (FDA) approval for Pasatru (garetosmab-grts) in a rare connective tissue disorder, placing it in direct competition with Ipsen's Sohonos (palovarotene).

Lilly's drug could cut the number of injections each patient needs by 85%.

Roche has conducted its joint-largest deal of the year so far, licensing a clinical-stage UCN2 (urocortin-2) analog being developed for weight loss by South Korea-based Hanmi Pharm.

The FDA approval marks another successful step in J&J's aim of achieving $5bn in peak sales for the drug.

PHP and ARCH have founded Sentivera, a biotech that now has an immunology licensing deal with China-based Haisco.

Study shows that those with low adherence of blood pressure-lowering drugs had significantly impaired therapeutic effect.

The Australia-based STAREE trial is the first of its kind demonstrating the preventative effects of statins in older patients.

Merida's lead programme, MER511, is in Phase I development for Graves' disease and thyroid eye disease (TED).

The antibody is designed to provide broad coverage across B-cell mediated diseases and might have autoimmune therapeutic potential. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. Access exclusive analyst commentary and expert insights View premium forecasts and data-driven pharmaceutical industry insights Stay up to date with pharma news, manufacturing innovation, and regulatory developments Receive alerts when new premium content is published Unlock free access Already have an account? Login here Unlock Free Access to Premium Content Already have an account? Login here

HMPL-A830 is an antibody-targeted therapy conjugate (ATTC) that selectively delivers a therapeutic drug to cancer cells, while sparing healthy tissue.